Table 6.

Anti-Obesity Drugs in Development. GLP-1 receptor agonists form the foundation of several anti-obesity drugs in development.

Therapeutic agent	Mechanism	Notes
Glucagon-like peptide – 1 receptor agonist (GLP-1 RA)	Slows gastric emptying, increases satiety, decreases hunger	GLP-RA that are approved anti-obesity medications include semaglutide and liraglutide. Agents in development include efpeglenatide, danuglipron (PF-06882961), LY3502970 and oral semaglutide [140,[158], [159], [160], [161]].